ZSB Sirona Biochem Corp

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that the Investing News Network has published an exclusive video interview with Dr. Geraldine Deliencourt-Godefroy, the Chief Scientific Officer of Sirona.

In the interview, Dr. Deliencourt-Godefroy shares the remarkable story behind her groundbreaking discovery in anti-aging, TFC-1326, and discusses the recent clinical trial that showed exceptional results in aging skin without any adverse side effects.

The interview is available for viewing on the Investing News Network's website at the following link: https://youtu.be/QgxKJUpk8o8.

About TFC-1326

The concept for the anti-aging library of compounds was initiated by Chief Scientific Officer Dr. Géraldine Deliencourt-Godefroy. The innovative chemistry is based on the naturally occurring glycoproteins found in polar fish. TFC-1326 is now a clinically proven breakthrough anti-aging compound. Sirona has achieved the goal to develop a non-invasive anti-aging skin care compound which is safe, easy to use and truly effective. TFC-1326 could be a stand-alone product for anti-aging or an adjunctive option to Botox® and dermal filler treatments depending on consumer goals.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.

BOTOX COSMETIC® is a registered trademark of Allergan Inc

For more information regarding this press release, please contact:Investor Enquiries:Email: Info@sironabiochem.com        

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

---------------------------------------------

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.